News articles about AveXis (NASDAQ:AVXS) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AveXis earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.6912026292793 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s analysis:
- Goldman Sachs Group, Inc. (The) Reiterates Buy Rating for AveXis, Inc. (AVXS) (americanbankingnews.com)
- Sukumar Nagendran Sells 1,780 Shares of AveXis, Inc. (AVXS) Stock (americanbankingnews.com)
- BRIEF-AveXis to report top-line data from phase 1 clinical trial of AVXS-101 (reuters.com)
- Featured Company News – AveXis Intends To Initiate Pivotal Trial Of AVXS-101 In SMA Type 1 On An Immediate Basis (finance.yahoo.com)
- AveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle Society (finance.yahoo.com)
AveXis (AVXS) opened at 100.49 on Tuesday. AveXis has a 52 week low of $43.06 and a 52 week high of $104.53. The firm has a 50-day moving average price of $94.22 and a 200-day moving average price of $82.99. The stock’s market capitalization is $3.21 billion.
AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.10). During the same quarter in the prior year, the company earned ($0.68) earnings per share. Equities research analysts predict that AveXis will post ($6.22) EPS for the current fiscal year.
A number of analysts recently weighed in on AVXS shares. BMO Capital Markets restated a “buy” rating and issued a $123.00 target price on shares of AveXis in a research report on Friday, August 11th. Zacks Investment Research upgraded AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Morgan Stanley restated an “overweight” rating and issued a $118.00 target price on shares of AveXis in a research report on Wednesday, August 9th. Citigroup Inc. set a $100.00 target price on AveXis and gave the stock a “buy” rating in a research report on Thursday, June 15th. Finally, Wells Fargo & Company restated an “outperform” rating and issued a $134.00 target price (up previously from $89.00) on shares of AveXis in a research report on Tuesday, September 5th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have assigned a buy rating to the company. AveXis has a consensus rating of “Buy” and a consensus target price of $106.31.
COPYRIGHT VIOLATION NOTICE: “AveXis (AVXS) Given Daily Media Impact Rating of 0.23” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://ledgergazette.com/2017/10/10/avexis-avxs-given-daily-media-impact-rating-of-0-23.html.
In other news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $93.25, for a total value of $165,985.00. Following the completion of the sale, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $165,985. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 5,340 shares of company stock valued at $501,996 over the last ninety days. Corporate insiders own 18.60% of the company’s stock.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.